Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 21:2022:1677621.
doi: 10.1155/2022/1677621. eCollection 2022.

Evaluation and Clinical Validation of Guanidine-Based Inactivation Transport Medium for Preservation of SARS-CoV-2

Affiliations

Evaluation and Clinical Validation of Guanidine-Based Inactivation Transport Medium for Preservation of SARS-CoV-2

Hesti L Wiraswati et al. Adv Pharmacol Pharm Sci. .

Abstract

WHO declared the outbreak of COVID-19, caused by SARS-CoV-2, a pandemic in March 2020. More than 223 million cases and approximately 4.6 million deaths have been confirmed. Early diagnosis and immediate treatment became a priority during this pandemic. However, COVID-19 diagnostic testing resources are limited, especially early in the pandemic. Apart from being limited, the COVID-19 diagnostic tests using reverse transcription polymerase chain reaction (RT-PCR) have encountered storage, transportation, and safety issues. These problems are mainly experienced by developing poor countries, countries in the equatorial region, and archipelagic countries. VITPAD® is a guanidine-based inactivation transport medium (ITM) formulated to maintain the RNA quality of SARS-CoV-2 during transportation without cold chains. This study, conducted from September 2020 to March 2021, performed clinical validation of VITPAD® by comparing its performance with a globally commercially available ITM from the NEST brand. Its stability at room temperature, safety, and resistance at high temperatures was also tested using RT-PCR analysis. VITPAD® can reduce the infectious nature of the specimen, preserve the SARS-CoV-2 for 18 days at an ambient temperature, and resist high temperatures (40°C for 3 hours). A guanidine-based transport medium, such as VITPAD®, is compatible and recommended for RT-PCR-based molecular diagnosis of COVID-19.

PubMed Disclaimer

Conflict of interest statement

The authors declared that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Calculation of the internal control cycle threshold value (IC CT value) of the Sansure reagent. (a) Samples stored in VITPAD® ITM: mean IC CT value = 24.22, standard deviation = 2.476, and number of sample = 99; (b) samples stored in NEST ITM mean IC CT value = 23.80, standard deviation = 1.601, and number of sample = 98.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curve. (a) Samples stored in VITPAD® ITM; (b) samples stored in NEST ITM.
Figure 3
Figure 3
CT value of target genes for the stability test at room temperature (±25°C). CT values of samples stored for 0 days, 4 days, 8 days, 12 days, and 18 days at room temperature (±25°C): (a) ORF1ab; (b) N-gene; and (c) E-gene. ns—not statistically significant. P-value >0.05 is considered not statistically significant.
Figure 4
Figure 4
CT value of target genes for the safety test. CT values of COVID-19 samples stored in VITPAD® ITM extracted with and without the lysis buffer: (a) ORF1ab; (b) N-gene; and (c) E-gene. ns—not statistically significant. P-value >0.05 is considered not statistically significant.
Figure 5
Figure 5
CT value of target genes for the resistance test. CT values of COVID-19 samples stored in VITPAD® ITM at room temperature (±25°C) and 40°C (for 3 hours): (a) ORF1ab; (b) N-gene; and (c) Internal control. ns—not statistically significant. P-value >0.05 is considered not statistically significant.

Similar articles

Cited by

References

    1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021. https://covid19.who.int/table .
    1. Tomo S., Karli S., Dharmalingam K., Yadav D., Sharma P. The clinical laboratory: a key player in diagnosis and management of COVID-19. EJIFCC . 2020;31(4):326–346. - PMC - PubMed
    1. Tu Y. P., O’Leary T. J. Testing for severe acute respiratory syndrome-coronavirus 2: challenges in getting good specimens, choosing the right test, and interpreting the results. Critical Care Medicine . 2020;48(11):1680–1689. doi: 10.1097/ccm.0000000000004594. - DOI - PMC - PubMed
    1. Esbin M. N., Whitney O. N., Chong S., Maurer A., Darzacq X., Tjian R. Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. RNA . 2020;26(7):771–783. doi: 10.1261/rna.076232.120. - DOI - PMC - PubMed
    1. Ravi N., Cortade D. L., Ng E., Wang S. X. Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosensors and Bioelectronics . 2020;165 doi: 10.1016/j.bios.2020.112454.112454 - DOI - PMC - PubMed

LinkOut - more resources